ArticleFrontiers in pediatrics2026
Machine learning based development of an early diagnosis signature for distinguishing hospitalized pediatric human respiratory syncytial virus infection from mycoplasma pneumonia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The differentiation between human respiratory syncytial virus (HRSV) and mycoplasma pneumoniae (MP) infections in pediatric community-acquired pneumonia (CAP) remains a clinical challenge due to overlapping respiratory symptoms. A rapid, non-invasive diagnostic tool is urgently needed to guide appropriate therapeutic decisions and antimicrobial stewardship. Objective: This study aimed to develop and validate a blood-based biomarker signature for distinguishing HRSV from MP infections. Methods: We conducted a retrospective cohort study analyzing clinical data and blood samples from patients with CAP infected by HRSV and MP, diagnosed via PCR and serology. Patients were randomly split into a discovery cohort and a validation cohort. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used for feature selection. ML was employed to train, optimize, and evaluate multiple classifiers, including logistic regression, random forest, and support vector machines. The diagnostic performance of the final model was evaluated by the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Results: The analysis identified a parsimonious five-biomarker signature comprising eosinophilic granulocyte, immunoglobulin A, lactic dehydrogenase (LDH), β2-microglobulin, and the albumin to globulinratio (AGR). The optimized random forest model demonstrated superior performance, achieving an AUC-ROC of 0.89 (95% CI: 0.85-0.90) for distinguishing HRSV from MP. Conclusion: We developed and validated a novel, minimally invasive blood biomarker signature that accurately distinguishes HRSV from MP infections. This model has the potential to serve as a valuable adjunctive tool for early etiological diagnosis, facilitating timely and targeted clinical management. Further prospective, multi-center studies are warranted to confirm its generalizability and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.